Chronic Spinal Cord InjuryNCT02136823
Impact of Persistent Conductances on Motor Unit Firing in SCI
A study testing sugar pill, Riluzole and Isradipine in people with Chronic Spinal Cord Injury, run by Shirley Ryan AbilityLab.
Trial summary
This study is being done to measure the differences between the electrical activity of muscles and /single muscle fibers in individuals with long-term spinal cord injury and neurologically intact individuals without spinal cord injury. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Chronic Spinal Cord Injury
- What is being tested?
- sugar pill, Riluzole and Isradipine
- Type of treatment
- Pill or oral medicine, Surgery or procedure
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 50 participants
- Where
- No sites listed yet
- Study dates
- Jun 2009to May 2015
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Subjects with Spinal Cord Injury:
- Clinical diagnosis of motor-incomplete chronic (>1yr) SCI between 18-65 yrs old
- non-progressive lesion between C5-T1
- movement impairment (including reduced volitional elbow flexion against gravity)
- reduced active range of motion
- medically stable
Show all 9Show fewer
- have medical clearance from their primary internists or physiatrists to participate in experiments involving drug administration.
- Control Subjects: healthy with no history of neurological injury or disease.
- have medical clearance from their primary internists or physiatrists to participate in experiments involving drug administration.
Who cannot join
- Under age 18yrs (children)
- Pregnancy or breastfeeding (women who are pregnant or nursing will be excluded)
- Spinal cord injury below T10 due to potential peripheral nerve damage/cauda equina injury
- concurrent medical illnesses, infections, upper extremity pain, inflammation or recent injury
- significant cardiovascular disease (including arrhythmias that require pacemakers, hypertension or hypotension)
- history of cardiovascular or pulmonary complications (including significant obstruction and/or restrictive lung diseases)
Show all 13Show fewer
- metabolic (endocrine, hepatic) or renal dysfuction
- traumatic head injury
- orthopedic disease or injury
- diagnosis of other neurological disease
- Concurrent use of antispasticity medications
- concurrent use of medications that may interact with the test agents
- previous sensitivity to the test agents or their components
About this study
This study is being done to measure the differences between the electrical activity of muscles and /single muscle fibers in individuals with long-term spinal cord injury and neurologically intact individuals without spinal cord injury. This study is also being done to find out if muscle and /single muscle fiber electrical activity, voluntary strength, reflex measurements, and/or spasms are changed after a single, oral dose of three commonly prescribed drugs, Rilutek®, isradipine, and Namenda®. These medications are approved by the FDA for treatment of disorders other than the control of spasms and strength. In this study, they are being used in an experimental manner. Finally, this study is also being done to find out whether or not a brief stretching exercise influences reflex measurements.
The main hypothesis of this study is that aberrant current activity in spinal motoneurons contributes to spastic hyper-reflexia following chronic spinal cord injury.
Read the detailed description
Background/Rationale/Literature Review
Hyper-reflexia, spasms and loss of motor coordination are common impairments in individuals with SCI. Though not thoroughly understood, recent studies suggest that persistent inward currents (PICs) in motoneurons play an important role in generating hyper-reflexia and involuntary spasms (Gorassini et al. 2004; Nickolls et al. 2004; Norton et al. 2008; Thomas et al. 2002). Animal models of chronic spinal cord injury point further to the differential involvement of increased sodium and calcium PICs in prolonged reflexes associated with spasticity (Harvey et al. 2006; Li and Bennett 2003; Li et al. 2004a; Li et al. 2004c). In addition, oral administration of the drug Rilutek®, a selective, progressive persistent sodium current inhibitor, has been shown to decrease flexion withdrawal responses in individuals with chronic SCI (Theiss et al. 2008), presumably because of the reduction of persistent sodium currents in participating neurons.
In addition to the loss of descending cortical drive, monoaminergic input to the spinal cord is also often disrupted in SCI. As hypothesized by Jacobs and Fornal (Jacobs and Fornal 1993; Jacobs et al. 2002), serotonin acts to facilitate motor output and inhibit sensory input. Removal of monoaminergic input in humans may therefore lead to motor weakness and hyperexcitable reflexes resulting in impaired motor function.
In addition to changes in facilitative or inhibitory modulation of spinal circuits, loss of descending monoaminergic input may also change the intrinsic excitability of the spinal neurons themselves. Following complete spinal transection, studies of electrical properties of spinal neurons below the lesion reveal that initially, interneurons, especially in the dorsal horn, become hyperexcitable, whereas motoneuron excitability plummets. In the motoneuron, a key factor in this drastic decrease is a loss of persistent inward currents (PICs). Persistent currents are conductances that, once activated, do not turn off, or at least inactivate at an extremely slow rate. PICs have a profound effect on the excitability of spinal neurons, both amplifying and prolonging their input (Prescott and De Koninck 2005) and allowing them to produce long lasting outputs, plateau potentials and bistable behavior (Heckman et al. 2005; Hounsgaard et al. 1984; Lee and Heckman 1998). The loss of PICs has such a strong impact that motoneurons produce only brief and weak outputs to the hyperexcitable interneuron inputs (Baldissera et al. 1981; Heckman 1994; Kehne et al. 1985; Nygren and Olson 1976).
In animal models of chronic injury, however, motoneuronal PICs return (Li and Bennett 2003; Li et al. 2004a), restoring the ability of motoneurons to produce sustained output in response to synaptic input. The return of motoneuronal PICs, which allows motoneurons to fully recover their ability to produce sustained output in response to synaptic input, coincides with the appearance of spasticity (Li et al. 2004b). In addition, blocking these PICs and long-lasting plateau potentials inhibits spastic behavior (Bennett et al. 2001a; Li et al. 2004a). To summarize, in the animal model of the chronic SCI condition, motoneurons demonstrate remarkable recovery of PICs, which likely play a major role in transmitting synaptic reflex inputs that generate spasticity.
Previous studies in animal models have shown that NaP is essential for the production of rhythmic firing to sustained or slowly rising inputs, such as the action potential afterhyperpolarization (AHP) (Kuo et al. 2006; Lee and Heckman 2001). Blocking NaP with riluzole decreases repetitive-firing capabilities (Harvey et al. 2006; Kuo et al. 2006; Kuo et al. 2005; Ptak et al. 2005; Theiss et al. 2007; Urbani and Belluzzi 2000) and reduces gain accompanied by a rightward bias shift in the input-output relation (Kuo et al. 2006; Theiss et al. 2007), which is indicative of an increase in input needed to initiate output. In addition, NaP amplifies and prolongs depolarization responses to brief stimuli (Prescott and De Koninck 2005). CaP, such as the L-type calcium current, are responsible for plateau potentials, which are a sustained depolarization following cessation of current input (Hounsgaard and Kiehn 1989; Morisset and Nagy 1999; Russo and Hounsgaard 1996; Voisin and Nagy 2001). In addition, CaP contributes to prolongation of depolarizing responses to brief stimuli (Prescott and De Koninck 2005).
In human studies, firing patterns in single motor units from chronic SCI subjects have shown differences in rate modulation (Thomas and Ross 1997), force-speed relations (Thomas et al. 1997), increases in discharge variability (Thomas et al. 2002), and prolonged duration of post-synaptic potentials in response to transient inputs using the PSF technique (Norton et al. 2008). These phenomena, especially those reflecting prolonged involuntary muscle activity in response to short duration stimuli, have been attributed to the presence of PICs in motoneurons. Recent results from Theiss (project co-investigator) et al. (2008) have also shown that administration of pharmacological agents that reduce PICs, e.g. riluzole, (which reduces NaP), decreases the flexion-withdrawal response in such a way that mimics the effects of riluzole seen in animal models. These are a right-ward bias shift and gain decrease in the input-output relation of animal spinal neurons (Kuo et al. 2006; Theiss et al. 2007). Interestingly, riluzole administration also enhanced agonist specificity in voluntary torque production by decreasing co-contraction and increasing total torque area during a maximum voluntary contraction (Theiss et al. 2008).
Several pharmacological agents that artificially reduce PICs in animal spinal neurons are available for human use. Riluzole, a specific, progressive NaP current inhibitor (Ptak et al. 2005; Urbani and Belluzzi 2000) has been proposed as a promising neuroprotective treatment for acute SCI (Baptiste and Fehlings 2006; Fehlings and Baptiste 2005; Hawryluk et al. 2008; Schwartz and Fehlings 2002). CaP current blockers, such as nimodipine, (Harvey et al. 2006; Li and Bennett 2003), have also been tested as a potential treatment in acute SCI to reduce neuronal excitability (Fehlings and Baptiste 2005; Pointillart et al. 2000; Winkler et al. 2003). Isradipine, a channel-specific CaP current blocker (Fitton and Benfield 1990), has been proposed as a preventative and acute treatment for Parkinson's disease (Surmeier 2007).
Interestingly, with the exception of investigations by Theiss (project co-investigator) and colleagues on the effects of riluzole and isradipine on flexion-withdrawal response and changes in volitional strength (Theiss et al. 2008, Theiss et al, 2011), the effects of either agent on motor function, spasms, spasticity and motor unit firing behaviors in chronic SCI have not been systematically studied. As studies by Theiss et al. (2008, 2011) have shown, they provide a safe mechanism to examine contributions of intrinsic neuronal currents to motor impairments.
Studies in animal models have also shown that NMDA-mediated currents have a role in the production of spastic reflexes in chronic SCI (Bennett et al, 2001b). These currents have been discussed as another possible contributor to prolonged spasms in human chronic SCI as well (Norton et al, 2008). Taking these additional studies into account, an additional aim is to expand our study to include preliminary investigation of a possible contribution of post-synaptic NMDA-mediated currents to spinal neuron excitability and hyperexcitable reflexes in chronic SCI.
Finally, muscle stretching is a commonly used, therapist-recommended clinical intervention for reducing the negative impact of spasticity on motor function (Smania et al 2010, Harvey \& Herbert 2002). As much as seven hours per week of therapy time is spent on stretching (Taylor-Schroeder et al 2011) and 27-41% of persons with SCI who undergo inpatient rehabilitation (Zanca et al 2011) report that they stretch as part of their rehabilitation program. However, there is no conclusive evidence at present that shows that stretching influences reflex excitability in persons with spinal cord injury (Bovend'Eerdt et al 2008).
Hypothesis/Key Questions, Research Objectives
The objectives of this study are to investigate the contribution of sodium and calcium persistent inward currents (PICs) towards mediating the hyper-reflexia and motor control impairments seen in chronic spinal cord injury (SCI) using targeted pharmacological agents. This study will test the hypothesis that aberrant current activity in spinal motoneurons contributes to spastic hyper-reflexia following chronic spinal cord injury. Three specific aims are proposed to evaluate this hypothesis:
- to investigate the key features that distinguish spastic muscle in chronic spinal cord injured individuals from that of spinally intact controls by assessing differences in single motor unit firing patterns and time course of responses to transient and sustained reflex inputs, as well as during voluntary control, and
- to dissect the relative impact of persistent sodium and persistent calcium conductances underlying the differences between spastic and non-spastic muscles by assessing changes in single motor unit firing patterns and time course following oral administration of Rilutek®, a persistent sodium current inhibitor, and isradipine, a persistent calcium current blocker.
- to investigate the impact of NMDA-mediated post-synaptic currents on the differences between spastic and non-spastic muscles by assessing changes in single motor unit firing patterns and reflex excitability following oral administration of memantine (Namenda®), a drug that decreases NMDA currents.
An additional objective of this study is to investigate the effects of a brief intermittent muscle elongation procedure on reflex excitability by testing reflex responses before and after a stretching intervention.
Research Purpose All procedures in this study are for research purposes.
This study will advance the understanding of the cellular mechanisms underlying hyperactive reflexes and loss of motor control in chronic SCI. Though not proposed as treatment agents at this stage, the pharmacological PIC antagonists and NMDA antagonist used in this study are intended as tools to understand the mechanisms of hyperexcitability. Therapeutically, the ability to manipulate neuronal excitability (e.g. to increase specificity in volitional strength or decrease hyper-reflexia) may lead to more effective treatments. Riluzole and isradipine provide artificial, yet specific, control of PICs. Memantine also provides a degree of control of synaptic NMDA-mediated post-synaptic currents. Understanding the cellular mechanisms of SCI impairments and their modulation may identify novel approaches to control spinal neuron excitability and provide appropriate tailoring of pharmacological treatments specific to the attributes of an individual's spasticity and impairments.
This study will also add to existing knowledge about the physiological effects of a commonly used yet with limited evidence base therapeutic intervention for reducing the negative impacts of reflex hyperexcitability on motor function in SCI.
- Conditions
- Chronic Spinal Cord Injury
- Being tested
- sugar pill, Riluzole, Isradipine, Memantine, Therapeutic muscle stretching
- Keywords
- Spinal Cord Injury
- Medical subject headings
- Spinal Cord Injuries
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
sugar pillDrug
Also called placebo
RiluzoleDrug
Also called Rilutek
IsradipineDrug
MemantineDrug
Also called Namenda
Therapeutic muscle stretchingProcedure or surgery
| Study group | Role | What they receive |
|---|---|---|
| sugar pill | Placebo comparator | sugar pill, oral administration, placebo capsule Receives: Drug: sugar pill |
| riluzole | Experimental | 50mg tablet, single oral dose, one day (single dose) Receives: Drug: Riluzole |
| isradipine | Experimental | 5mg capsule, single oral dose, one day (single dose) Receives: Drug: Isradipine |
| memantine | Experimental | 5mg tablet, single oral dose, one day (single oral dose) Receives: Drug: Memantine |
| therapeutic stretching | Experimental | Manual therapeutic stretching of tested muscle by licensed clinician Receives: Procedure: Therapeutic muscle stretching |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in reflex excitability measures following drug administration
Measured: up to 8 hours
Change in reflex excitability measures after muscle stretching intervention
Measured: up to 6 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 May 2014 (estimated)
- Study startJun 2009
- Primary completionMay 2015 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Spinal Cord InjuryStudies of the same condition, open and under way.
- More trials run by Shirley Ryan AbilityLabThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Shirley Ryan AbilityLab
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Renee Theiss, Shirley Ryan AbilityLab
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02136823
- Sponsor's protocol ID
- STU00012823
- Status last verified
- May 2014
- First submitted
- 9 May 2014
- Last updated
- 13 May 2014
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 May 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of Persistent Conductances on Motor Unit Firing in SCI
- ClinicalTrials.gov ID
- NCT02136823
- Acronym / sponsor ID
- STU00012823
- Conditions
- Chronic Spinal Cord Injury
- Keywords
- Spinal Cord Injury
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Shirley Ryan AbilityLabUniversity, hospital or other
- Study start
- Jun 2009
- Primary completion
- May 2015 (estimated)
- First posted
- 13 May 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is being done to measure the differences between the electrical activity of muscles and /single muscle fibers in individuals with long-term spinal cord injury and neurologically intact individuals without spinal cord injury. This study is also being done to find out if muscle and /single muscle fiber electrical activity, voluntary strength, reflex measurements, and/or spasms are changed after a single, oral dose of three commonly prescribed drugs, Rilutek®, isradipine, and Namenda®. These medications are approved by the FDA for treatment of disorders other than the control of spasms and strength. In this study, they are being used in an experimental manner. Finally, this study is also being done to find out whether or not a brief stretching exercise influences reflex measurements.
The main hypothesis of this study is that aberrant current activity in spinal motoneurons contributes to spastic hyper-reflexia following chronic spinal cord injury.
Detailed description
Background/Rationale/Literature Review
Hyper-reflexia, spasms and loss of motor coordination are common impairments in individuals with SCI. Though not thoroughly understood, recent studies suggest that persistent inward currents (PICs) in motoneurons play an important role in generating hyper-reflexia and involuntary spasms (Gorassini et al. 2004; Nickolls et al. 2004; Norton et al. 2008; Thomas et al. 2002). Animal models of chronic spinal cord injury point further to the differential involvement of increased sodium and calcium PICs in prolonged reflexes associated with spasticity (Harvey et al. 2006; Li and Bennett 2003; Li et al. 2004a; Li et al. 2004c). In addition, oral administration of the drug Rilutek®, a selective, progressive persistent sodium current inhibitor, has been shown to decrease flexion withdrawal responses in individuals with chronic SCI (Theiss et al. 2008), presumably because of the reduction of persistent sodium currents in participating neurons.
In addition to the loss of descending cortical drive, monoaminergic input to the spinal cord is also often disrupted in SCI. As hypothesized by Jacobs and Fornal (Jacobs and Fornal 1993; Jacobs et al. 2002), serotonin acts to facilitate motor output and inhibit sensory input. Removal of monoaminergic input in humans may therefore lead to motor weakness and hyperexcitable reflexes resulting in impaired motor function.
In addition to changes in facilitative or inhibitory modulation of spinal circuits, loss of descending monoaminergic input may also change the intrinsic excitability of the spinal neurons themselves. Following complete spinal transection, studies of electrical properties of spinal neurons below the lesion reveal that initially, interneurons, especially in the dorsal horn, become hyperexcitable, whereas motoneuron excitability plummets. In the motoneuron, a key factor in this drastic decrease is a loss of persistent inward currents (PICs). Persistent currents are conductances that, once activated, do not turn off, or at least inactivate at an extremely slow rate. PICs have a profound effect on the excitability of spinal neurons, both amplifying and prolonging their input (Prescott and De Koninck 2005) and allowing them to produce long lasting outputs, plateau potentials and bistable behavior (Heckman et al. 2005; Hounsgaard et al. 1984; Lee and Heckman 1998). The loss of PICs has such a strong impact that motoneurons produce only brief and weak outputs to the hyperexcitable interneuron inputs (Baldissera et al. 1981; Heckman 1994; Kehne et al. 1985; Nygren and Olson 1976).
In animal models of chronic injury, however, motoneuronal PICs return (Li and Bennett 2003; Li et al. 2004a), restoring the ability of motoneurons to produce sustained output in response to synaptic input. The return of motoneuronal PICs, which allows motoneurons to fully recover their ability to produce sustained output in response to synaptic input, coincides with the appearance of spasticity (Li et al. 2004b). In addition, blocking these PICs and long-lasting plateau potentials inhibits spastic behavior (Bennett et al. 2001a; Li et al. 2004a). To summarize, in the animal model of the chronic SCI condition, motoneurons demonstrate remarkable recovery of PICs, which likely play a major role in transmitting synaptic reflex inputs that generate spasticity.
Previous studies in animal models have shown that NaP is essential for the production of rhythmic firing to sustained or slowly rising inputs, such as the action potential afterhyperpolarization (AHP) (Kuo et al. 2006; Lee and Heckman 2001). Blocking NaP with riluzole decreases repetitive-firing capabilities (Harvey et al. 2006; Kuo et al. 2006; Kuo et al. 2005; Ptak et al. 2005; Theiss et al. 2007; Urbani and Belluzzi 2000) and reduces gain accompanied by a rightward bias shift in the input-output relation (Kuo et al. 2006; Theiss et al. 2007), which is indicative of an increase in input needed to initiate output. In addition, NaP amplifies and prolongs depolarization responses to brief stimuli (Prescott and De Koninck 2005). CaP, such as the L-type calcium current, are responsible for plateau potentials, which are a sustained depolarization following cessation of current input (Hounsgaard and Kiehn 1989; Morisset and Nagy 1999; Russo and Hounsgaard 1996; Voisin and Nagy 2001). In addition, CaP contributes to prolongation of depolarizing responses to brief stimuli (Prescott and De Koninck 2005).
In human studies, firing patterns in single motor units from chronic SCI subjects have shown differences in rate modulation (Thomas and Ross 1997), force-speed relations (Thomas et al. 1997), increases in discharge variability (Thomas et al. 2002), and prolonged duration of post-synaptic potentials in response to transient inputs using the PSF technique (Norton et al. 2008). These phenomena, especially those reflecting prolonged involuntary muscle activity in response to short duration stimuli, have been attributed to the presence of PICs in motoneurons. Recent results from Theiss (project co-investigator) et al. (2008) have also shown that administration of pharmacological agents that reduce PICs, e.g. riluzole, (which reduces NaP), decreases the flexion-withdrawal response in such a way that mimics the effects of riluzole seen in animal models. These are a right-ward bias shift and gain decrease in the input-output relation of animal spinal neurons (Kuo et al. 2006; Theiss et al. 2007). Interestingly, riluzole administration also enhanced agonist specificity in voluntary torque production by decreasing co-contraction and increasing total torque area during a maximum voluntary contraction (Theiss et al. 2008).
Several pharmacological agents that artificially reduce PICs in animal spinal neurons are available for human use. Riluzole, a specific, progressive NaP current inhibitor (Ptak et al. 2005; Urbani and Belluzzi 2000) has been proposed as a promising neuroprotective treatment for acute SCI (Baptiste and Fehlings 2006; Fehlings and Baptiste 2005; Hawryluk et al. 2008; Schwartz and Fehlings 2002). CaP current blockers, such as nimodipine, (Harvey et al. 2006; Li and Bennett 2003), have also been tested as a potential treatment in acute SCI to reduce neuronal excitability (Fehlings and Baptiste 2005; Pointillart et al. 2000; Winkler et al. 2003). Isradipine, a channel-specific CaP current blocker (Fitton and Benfield 1990), has been proposed as a preventative and acute treatment for Parkinson's disease (Surmeier 2007).
Interestingly, with the exception of investigations by Theiss (project co-investigator) and colleagues on the effects of riluzole and isradipine on flexion-withdrawal response and changes in volitional strength (Theiss et al. 2008, Theiss et al, 2011), the effects of either agent on motor function, spasms, spasticity and motor unit firing behaviors in chronic SCI have not been systematically studied. As studies by Theiss et al. (2008, 2011) have shown, they provide a safe mechanism to examine contributions of intrinsic neuronal currents to motor impairments.
Studies in animal models have also shown that NMDA-mediated currents have a role in the production of spastic reflexes in chronic SCI (Bennett et al, 2001b). These currents have been discussed as another possible contributor to prolonged spasms in human chronic SCI as well (Norton et al, 2008). Taking these additional studies into account, an additional aim is to expand our study to include preliminary investigation of a possible contribution of post-synaptic NMDA-mediated currents to spinal neuron excitability and hyperexcitable reflexes in chronic SCI.
Finally, muscle stretching is a commonly used, therapist-recommended clinical intervention for reducing the negative impact of spasticity on motor function (Smania et al 2010, Harvey \& Herbert 2002). As much as seven hours per week of therapy time is spent on stretching (Taylor-Schroeder et al 2011) and 27-41% of persons with SCI who undergo inpatient rehabilitation (Zanca et al 2011) report that they stretch as part of their rehabilitation program. However, there is no conclusive evidence at present that shows that stretching influences reflex excitability in persons with spinal cord injury (Bovend'Eerdt et al 2008).
Hypothesis/Key Questions, Research Objectives
The objectives of this study are to investigate the contribution of sodium and calcium persistent inward currents (PICs) towards mediating the hyper-reflexia and motor control impairments seen in chronic spinal cord injury (SCI) using targeted pharmacological agents. This study will test the hypothesis that aberrant current activity in spinal motoneurons contributes to spastic hyper-reflexia following chronic spinal cord injury. Three specific aims are proposed to evaluate this hypothesis:
- to investigate the key features that distinguish spastic muscle in chronic spinal cord injured individuals from that of spinally intact controls by assessing differences in single motor unit firing patterns and time course of responses to transient and sustained reflex inputs, as well as during voluntary control, and
- to dissect the relative impact of persistent sodium and persistent calcium conductances underlying the differences between spastic and non-spastic muscles by assessing changes in single motor unit firing patterns and time course following oral administration of Rilutek®, a persistent sodium current inhibitor, and isradipine, a persistent calcium current blocker.
- to investigate the impact of NMDA-mediated post-synaptic currents on the differences between spastic and non-spastic muscles by assessing changes in single motor unit firing patterns and reflex excitability following oral administration of memantine (Namenda®), a drug that decreases NMDA currents.
An additional objective of this study is to investigate the effects of a brief intermittent muscle elongation procedure on reflex excitability by testing reflex responses before and after a stretching intervention.
Research Purpose All procedures in this study are for research purposes.
This study will advance the understanding of the cellular mechanisms underlying hyperactive reflexes and loss of motor control in chronic SCI. Though not proposed as treatment agents at this stage, the pharmacological PIC antagonists and NMDA antagonist used in this study are intended as tools to understand the mechanisms of hyperexcitability. Therapeutically, the ability to manipulate neuronal excitability (e.g. to increase specificity in volitional strength or decrease hyper-reflexia) may lead to more effective treatments. Riluzole and isradipine provide artificial, yet specific, control of PICs. Memantine also provides a degree of control of synaptic NMDA-mediated post-synaptic currents. Understanding the cellular mechanisms of SCI impairments and their modulation may identify novel approaches to control spinal neuron excitability and provide appropriate tailoring of pharmacological treatments specific to the attributes of an individual's spasticity and impairments.
This study will also add to existing knowledge about the physiological effects of a commonly used yet with limited evidence base therapeutic intervention for reducing the negative impacts of reflex hyperexcitability on motor function in SCI.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| sugar pill | Placebo comparator | Drug: sugar pillsugar pill, oral administration, placebo capsule |
| riluzole | Experimental | Drug: Riluzole50mg tablet, single oral dose, one day (single dose) |
| isradipine | Experimental | Drug: Isradipine5mg capsule, single oral dose, one day (single dose) |
| memantine | Experimental | Drug: Memantine5mg tablet, single oral dose, one day (single oral dose) |
| therapeutic stretching | Experimental | Procedure: Therapeutic muscle stretchingManual therapeutic stretching of tested muscle by licensed clinician |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Subjects with Spinal Cord Injury:
- Control Subjects: healthy with no history of neurological injury or disease.
Key exclusion criteria (13 listed)
- Under age 18yrs (children)
- Pregnancy or breastfeeding (women who are pregnant or nursing will be excluded)
- Spinal cord injury below T10 due to potential peripheral nerve damage/cauda equina injury
- concurrent medical illnesses, infections, upper extremity pain, inflammation or recent injury
- significant cardiovascular disease (including arrhythmias that require pacemakers, hypertension or hypotension)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| sugar pillAlso: placebo | Drug | sugar pill |
| RiluzoleAlso: Rilutek | Drug | riluzole |
| Isradipine | Drug | isradipine |
| MemantineAlso: Namenda | Drug | memantine |
| Therapeutic muscle stretching | Procedure or surgery | therapeutic stretching |
Primary outcome
Changes in reflex excitability measures following drug administration
Time frame: up to 8 hours
Change in reflex excitability measures after muscle stretching intervention
Time frame: up to 6 hours
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 May 2014.
Related trials for Chronic Spinal Cord Injury
RecruitingPhase 3
A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury
Chronic Spinal Cord Injury
RecruitingPhase 2/3
Pilot Study of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI)
Spinal Cord Injury, Traumatic Spinal Cord Injury
Active, not recruitingObservational study
SCIVAX: Biomarkers of Immune Dysfunction and Vaccine Responsiveness in Chronic SCI
Spinal Cord Injuries, Traumatic Spinal Cord Injury
Enrolling by invitation
Long-Term Clinical, Health Economic, and Process Evaluation of Intensive Technology-Integrated Motor Rehabilitation in Chronic Neurological Conditions (INTeRAcT-bis)
Stroke, Spinal Cord Injuries (SCI)
Recruiting
Virtual Reality-Based Hypnotherapy for Pain, Sleep, and Mood in Spinal Cord Injury
Spinal Cord Injuries (SCI), Chronic Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing sugar pill, Riluzole and Isradipine in people with Chronic Spinal Cord Injury, run by Shirley Ryan AbilityLab.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 13 May 2014. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in reflex excitability measures following drug administration (time frame: up to 8 hours). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 May 2014.